Crinetics Pharmaceuticals, Inc. (CRNX) Covered Calls

Crinetics Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company specializes in targeting G-protein coupled receptors (GPCRs) with orally administered small molecules. Its lead product, Palsonify, is an approved therapy for acromegaly, providing an oral alternative to traditional injectable somatostatin receptor ligands.

You can sell covered calls on Crinetics Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CRNX (prices last updated Fri 4:16 PM ET):

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
42.70 -1.38 42.00 42.69 1.4M - 4.2
Covered Calls For Crinetics Pharmaceuticals, Inc. (CRNX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 43 0.00 42.69 0.0% 0.0%
Mar 20 43 1.30 41.39 3.1% 31.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Crinetics Pharmaceuticals is a leader in endocrine-focused drug development, utilizing its deep expertise in GPCR pharmacology. The company’s commercial flagship is Palsonify (paltusotine), the first once-daily oral somatostatin receptor type 2 (SST2) agonist approved for the treatment of acromegaly. Beyond acromegaly, the company is advancing a robust pipeline that includes atumelnant, an oral candidate for congenital adrenal hyperplasia (CAH) and Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate targeting neuroendocrine tumors. Their proprietary platform allows for the design of small molecules that mimic the efficacy of larger peptide-based biologics but offer the convenience of oral administration.

Competitive Landscape

Crinetics operates in a specialized endocrine market where it competes with both established pharmaceutical giants and biotech peers. In the acromegaly and carcinoid syndrome space, its primary competitors are Novartis AG and specialized peptide firms. In the broader metabolic and GPCR-targeted biotech sector, it is often compared to Structure Therapeutics Inc. and Viking Therapeutics, Inc.. Other peers in rare endocrine and hormonal diseases include Ascendis Pharma A/S and Ultragenyx Pharmaceutical Inc.. The company differentiates itself through its "oral-first" strategy, aiming to replace the burden of lifelong injections with once-daily pills.

Strategic Outlook and Innovation

The company is currently executing its "Silicon-to-Systems" transformation, evolving into a fully integrated global commercial organization. Strategic innovation is focused on the expansion of its platform into new therapeutic areas like Graves’ disease, polycystic kidney disease, and obesity. A major focus is the late-stage development of atumelnant, which aims to address the hormonal imbalances of CAH by selectively blocking ACTH activity at the adrenal gland. Crinetics is also pioneering "nonpeptide drug conjugates" (NDCs), a novel modality that combines the targeting precision of GPCR ligands with therapeutic payloads. Supported by a robust cash runway, the firm is investing heavily in its commercial infrastructure and payer engagement to establish its oral therapies as the new standard of care in the global endocrine market.